Skip to Content
Merck
All Photos(1)

Documents

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Synonym(s):

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H17NO7P2
CAS Number:
79778-41-9
Molecular Weight:
277.15
MDL number:
MFCD00866995
UNSPSC Code:
51111800
PubChem Substance ID:
24724553
NACRES:
NA.77

product name

Neridronate, ≥97% (NMR), solid

description

may contain <1% (w/w) inorganic salts

Quality Level

100

Assay

≥97% (NMR)

form

solid

color

white

solubility

H2O: >5 mg/mL

storage temp.

2-8°C

SMILES string

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

InChI key

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Biochem/physiol Actions

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Benucci et al.
Clinical and experimental rheumatology, 27(4), 567-573 (2009-09-24)
To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and
Patrizia D'Eufemia et al.
Pediatric research, 63(2), 203-206 (2007-12-20)
Prostaglandin E2 (PGE2) is an activator of bone remodeling, and increase levels of PGE2 are found in several disorders characterized by chronic inflammation. Bisphosphonates are used in the treatment of osteogenesis imperfecta (OI), an inherited disorder characterized by bone fragility
Pietro Persiani et al.
Medicine, 96(20), e6766-e6766 (2017-05-18)
The purpose of this study is to compare the results of 2 techniques, tension band wiring (TBW) and fixation with screws, in olecranon fractures in children affected with osteogenesis imperfecta (OI) type I. Between 2010 and 2014, 21 olecranon fractures
Silvano Adami et al.
Calcified tissue international, 83(5), 301-307 (2008-10-24)
Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramuscularly (IM), was tested in a phase 2
Aino-Liisa Saari et al.
Molecules (Basel, Switzerland), 17(9), 10928-10945 (2012-09-14)
Aminobisphosphonates, e.g., alendronate and neridronate, are a well known class of molecules used as drugs for various bone diseases. Although these molecules have been available for decades, a detailed understanding of their most important physicochemical properties under comparable conditions is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service